Summary of clinical feature of patients with PV treated with idasanutlin with TP53 mutant clones
| Patient . | Age, y . | Sex . | Time on study, wk . | No. of TP53 mutations . | Clinical response . | Prior therapy . |
|---|---|---|---|---|---|---|
| 1 | 68 | Female | 105.1 | 1 | PR | HU, IFN |
| 2 | 48 | Male | 85.1 | 5 | PR | IFN |
| 3 | 52 | Female | 90.9 | 1 | CR | HU |
| 4 | 65 | Male | 70.1 | 3 | CR | HU |
| 5 | 83 | Female | 37.1 | 2 | NR | HU |
| Patient . | Age, y . | Sex . | Time on study, wk . | No. of TP53 mutations . | Clinical response . | Prior therapy . |
|---|---|---|---|---|---|---|
| 1 | 68 | Female | 105.1 | 1 | PR | HU, IFN |
| 2 | 48 | Male | 85.1 | 5 | PR | IFN |
| 3 | 52 | Female | 90.9 | 1 | CR | HU |
| 4 | 65 | Male | 70.1 | 3 | CR | HU |
| 5 | 83 | Female | 37.1 | 2 | NR | HU |
Clinical responses were assessed by using European LeukemiaNet criteria.
CR, complete response; HU, hydroxyurea; IFN, interferon; NR, no response; PR, partial response.